# Sun Pharma to consider ₹15,000 crore NCD issue

> Sun Pharma plans ₹15,000 crore debt sale to fund Organon acquisition bridge loan.
- Title: Sun Pharma to consider ₹15,000 crore NCD issue · mint
- Summary: Sun Pharma plans ₹15,000 crore debt sale to fund Organon acquisition bridge loan. Sun Pharma will issue up to ₹15,000 crore non-convertible debentures to…
- Keywords: sun pharma, organon co, ncd issue, bridge loan, debt sale, pharma, india, money, business, Sun, consider, 000
- Source: mint — https://livemint.com/market/stock-market-news/sun-pharma-to-consider-rs-15-000-crore-ncd-issue-board-meeting-on-12-october-11791390670328.html
- Author: A Ksheerasagar
- Published: 2026-10-07T17:03:30+00:00
- Read time: 1 min
- Topics: sun pharma, organon co, ncd issue, bridge loan, debt sale, pharma, india, money, business
## Sun Pharma board meeting
Sun Pharmaceutical Industries will hold a board meeting on October 12, 2026.
## ₹15,000 crore NCD issuance
The company plans to issue non-convertible debentures worth up to ₹ 15,000 crore.
## Bridge loan for Organon acquisition
The debt sale funds a bridge loan to acquire US healthcare company Organon & Co.
## Private placement basis
The NCD issuance will be on a private placement basis in one or more tranches.
## Reuters report on bridge loan
Reuters reported the company closed a $12 billion 18-month bridge loan earlier this year.
## LIB Therapeutics deal
Sun Pharma signed an exclusive agreement with LIB Therapeutics for lerodalcibep manufacturing.
## Lerodalcibep market potential
The drug targets a $3.7 billion PCSK9 market outside US and China growing at 38% CAGR.
## Q1 financial results
Sun Pharma reported 27% rise in net profit to ₹ 2,894.79 crore for June quarter.
## Key takeaway

Sun Pharma will issue up to ₹15,000 crore non-convertible debentures to fund a bridge loan for acquiring US healthcare company Organon & Co.